Japan’s largest drugmaker, Takeda Pharmaceuticals, announced it is working with the European Medicines Agency (EMA) to ...

RemeGen’s Phase III trial of disitamab vedotin shows improved progression-free survival in advanced breast cancer patients ...

Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned ...

Switzerland’s Galderma has won US Food and Drug Administration (FDA) approval for the use of Nemluvio (nemolizumab) for ...

The schizophrenia market across the seven major markets is poised to grow at a compound annual growth rate (CAGR) of 7.4% ...

Denmark-based diabetes and obesity giant Novo Nordisk says it plans to invest 8.5 billion Danish kroner ($1.2 billion) to ...

Shares of Swedish pharma firm Orexo leapt 20.2% to 20.60 kronor this morning, following its announcement over the weekend ...

VectorY Therapeutics appoints Jim Scibetta as CEO to lead development of VTx-002, a vectorized antibody therapy targeting TDP ...

UK-based Puretech Health has announced positive results from ELEVATE IPF, a Phase IIb trial of deupirfenidone (LYT-100) at ...

BioNTech resumes its PRESERVE-003 trial for gotistobart as a monotherapy in metastatic squamous NSCLC after a partial ...

The buy will bolster Pharming’s pipeline with Abliva’s lead asset, KL1333, a promising therapy for mitochondrial disease.

US biotech Checkpoint Therapeutics saw its shares jump more than 16% to $4.27 in after-hours trading on Friday, on the news ...